Yazar "Şahin A." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Experiential investigation of nonlinear acoustic field structure in two and three dimensions
    (Institute of Electrical and Electronics Engineers Inc., 2016) Kaleci D.; Şahin A.; Karaböcü B.
    In this paper, two and three dimensional experimental nonlinear acoustic pressure fields that are produced by circular sources are presented. We developed an experiment systems to measure results of nonlinear acoustic pressure fields for the first three harmonic components along both acoustic and radial axis, in both two and three dimensions. The use of sub-harmonics to improve the lateral and axial image quality is also discussed. In addition, the experimental results are compared with theoretical results for the first three harmonics and are observed to essentially consistent with the theoretical results. © 2016 IEEE.
  • Küçük Resim Yok
    Öğe
    Overcoming the challenges of drug resistance through combination drug delivery approach
    (Elsevier, 2022) Tonbul H.; Şahin A.; Çapan Y.
    Anticancer and antimicrobial drug resistances are the most important problems that decrease the overall success of drug treatment in the clinic. The combination of two or more different kinds of drugs in clinical practice has been generally accepted as a feasible strategy to achieve superior therapeutic efficacy. However, codelivery of drugs in free form may fail due to different solubility, pharmacokinetic behavior, and stability problems. Drug delivery systems, mainly nanoparticulate systems, hold the big potential to achieve this problem. In this chapter, different approaches used in combination therapy to overcome drug resistance are discussed. © 2022 Elsevier Inc. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Regulatory Guidelines of the US Food and Drug Administration and the European Medicines Agency for Actively Targeted Nanomedicines
    (Taylor and Francis, 2021) Çetintaş H.C.; Tonbul H.; Şahin A.; Çapan Y.
    Guidelines for nanomedicines that are published by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are listed later. This chapter reviews the current FDA and EMA regulatory guidelines for nanomedicines and evaluate their potential for use as reference for actively targeted nanomedicines. The FDA has recommended determining critical quality attributes that have a potential impact on product performance and utilize risk assessments that link structure–function relationships. The FDA recommends considering some points for selecting and using characterization methods. The FDA obligates to manufacture nanomaterials containing drugs in accordance with Good Manufacturing Practices similar to all drug products. The FDA states that all existing International Conference on Harmonization guidelines addressing nonclinical studies be generally applicable for nanomaterials containing drugs. The FDA states that the drug release characteristics of liposomes should be analyzed and release differences between liposomal and nonliposomal formulations should be added to the application. © 2022 Jenny Stanford Publishing Pte. Ltd.